1. Role of CXCL13 in asthma: novel therapeutic target.
- Author
-
Baay-Guzman GJ, Huerta-Yepez S, Vega MI, Aguilar-Leon D, Campillos M, Blake J, Benes V, Hernandez-Pando R, Teran LM, Baay-Guzman, Guillermina Juliana, Huerta-Yepez, Sara, Vega, Mario I, Aguilar-Leon, Diana, Campillos, Monica, Blake, Jonathon, Benes, Vladimir, Hernandez-Pando, Rogelio, and Teran, Luis M
- Abstract
Background: B cells play an important role in allergic asthma. However, the mechanisms by which these cells are activated in the airways remain poorly understood.Methods: We used a mouse model of ovalbumin (OVA)-induced allergic inflammation to study CXCL13 and to investigate the concentration of this chemokine in the BAL fluid derived from asthmatic and normal control subjects.Results: We found that OVA-challenged mice upregulate the CXCL13/CXCR5 axis, which is associated with several changes in their airways, including recruitment of B and CD4(+) cells, development of bronchial-associated lymphoid tissue, and airway inflammation. Treating sensitized mice with an anti-CXCL13 antibody reduced cell recruitment, bronchial-associated lymphoid tissue formation, and airways inflammation. Interestingly, measurements of CXCL13 using enzyme-linked immunosorbent assay showed that levels of this cytokine were significantly elevated in BAL fluid from subjects with asthma compared with control subjects (median, 162 [range, 120-296] vs 31 [range, 120-156] pg/mL; P = .005).Conclusions: All together, these findings suggest that CXCL13 is involved in the allergic airway inflammatory process, and targeting this chemokine may constitute a novel approach in asthma. [ABSTRACT FROM AUTHOR]- Published
- 2012
- Full Text
- View/download PDF